TREATMENT OF OCULAR DISEASES USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL)PHENYL)-3-[4-(4,6- DIMORPHOLIN-4- YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA - Patent 4823581

(19)

(11)

EP 4 823 581 A1

(12)

(43)	Date of publication:
	21.10.2026 Bulletin 2026/43

(21)	Application number: 24829332.6

(22)	Date of filing: 11.12.2024

(51)

International Patent Classification (IPC):

A61K 31/5377^(2006.01)
A61P 27/02^(2006.01)

A61K 45/06^(2006.01)
A61K 9/00^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/5377; A61K 45/06; A61P 27/02; A61K 9/0048; A61K 9/08

	C-Sets:
	A61K 31/5377, A61K 2300/00;

(86)	International application number:
	PCT/US2024/059586

(87)	International publication number:
	WO 2025/128712 (19.06.2025 Gazette 2025/25)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA
	Designated Validation States:
	GE KH MA MD TN

(30)

Priority:

12.12.2023 US 202363609230 P

(71)	Applicant: Celcuity Inc.
	Minneapolis, MN 55441 (US)

(72)	Inventors:
	LAING, Lance, Gavin Minneapolis, Minnesota 55441 (US) MACNEIL, Ian Milton, MA 02186 (US) SULLIVAN, Brian, Francis Minneapolis, Minnesota 55441 (US)

(74)	Representative: J A Kemp LLP
	80 Turnmill Street London EC1M 5QU London EC1M 5QU (GB)

(54)	TREATMENT OF OCULAR DISEASES USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL)PHENYL)-3-[4-(4,6- DIMORPHOLIN-4- YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA